Zolmitriptan 139264-17-8 Anti-migraine USP Standard Quick Effect

Basic Information
Place of Origin: CHINA
Brand Name: TINGYI
Certification: GMP , ISO 9001:2008
Model Number: 139264-17-8
Minimum Order Quantity: 10g
Price: Contact Me
Packaging Details: Disguised Package
Delivery Time: 2 Working Days
Payment Terms: Bank Transfer - Bitcoin - Western Union - MoneyGram
Supply Ability: 100 KG/Month
Product Name: Zolmitriptan CAS: 139264-17-8
Appearance: White Powder Usage: Anti-migraine
Shipping Method: EMS, HKEMS, FEDEX, DHL, UPS, Aramex, ETC Color: White
High Light:

pharmaceutical active ingredients


pharmaceutical anabolic steroids

Basic Information

Product Name Zolmitriptan
CAS 139264-17-8
Purity 99%
Molecular Formula C16H21N3O2
Molecular Weight 287.35684
EINECS 629-919-0
Molecular Structure Zolmitriptan 139264-17-8 Anti-migraine USP Standard Quick Effect 0
Payment Method

Western Union, Bank Transfer, MoneyGram, Bitcoin, Litecoin






Item Standard Result
Appearance white to off-white powder off-white powder
solubility soluble in methanol complies
identification IR/HPLC complies
Melting range 136~141deg.C 136.6~138.5Deg.C%
a[D] -4.5~-8.5Deg -6.2deg
redisue on ignition 0.1% max 0.05%
Heavy metals 10ppm max complies
loss on drying 0.5% max 0.25%
related substaces    
single impurity 0.5% max 0.15%
total impurity 1.0% max 0.31%
Assay 99%-101.5% 99.90%





Medical uses

Zolmitriptan is used for the acute treatment of migraines with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine.


Zolmitriptan is available as a swallowable tablet, an oral disintegrating tablet, and a nasal spray, in doses of 2.5 and 5 mg. People who get migraines from aspartame should not use the disintegrating tablet (Zomig ZMT), which contains aspartame.


According to a study of healthy volunteers, food intake seems to have no significant effect on the effectiveness of Zolmitriptan in both men and women.




Contraindications and precautions

Zolmitriptan should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's angina, or other significant underlying cardiovascular disease.


Zolmitriptan may increase blood pressure, it should not be given to patients with uncontrolled hypertension, should not be used within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide, and should not be administered to patients with hemiplegic or basilar migraine.


Concurrent administration of MAOI or use of zolmitriptan within 2 weeks of discontinuation of MAO-A inhibitor therapy is contraindicated.




Adverse reactions

The Zomig ZMT dissolvable pill contains aspartame, and should be avoided by anyone sensitive to that ingredient and by those suffering from phenylketonuria.


Rarely, serious cardiac events, including myocardial infarction (heart attack), have been associated with zolmitriptan.


Reported minor adverse reactions include: hypesthesia, paresthesia (all types), warm and cold sensations, chest pain, throat and jaw tightness, dry mouth, dyspepsia, dysphagia, nausea, somnolence, vertigo, asthenia, myalgia, myasthenia and sweating.


Following administration of cimetidine, the half-life and AUC of zolmitriptan and its active metabolites were approximately doubled (see CLINICAL PHARMACOLOGY in product pamphlet). Cimetidine is a histamine H2-receptor antagonist that inhibits the production of acid in the stomach.






Zolmitriptan is a synthetic tryptamine derivative and appears as a white powder that is partially soluble in water.



Contact Details
Sales Manager

WhatsApp : +8613657291547